Rare Cancers – more common than you think
ESMO Sarcoma & GIST 2018: Round table with SPAEN
More than 4 million people in the European Union are affected by rare cancers. Despite the rarity of each of more than 200 rare cancers, they represent in total about 24% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year. Moreover, common cancers are rapidly subdividing into their own subgroups.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda and to implementing 39 political and stakeholder recommendations.
-
Rare Cancers: The Challenges
- Late or incorrect diagnosis
- Lack of access to appropriate therapies and clinical expertise
- Very limited number of clinical studies due to the small number of patients -
Specific clinical trial methodology needed for rare cancers
RCE calls for new criteria to be used in clinical trials on rare cancer treatments. Read the full article.
-
Rare Cancers: Pathologic Diagnosis
Rare Cancers Europe Consensus Statement summary on the urgent actions needed to improve pathologic diagnosis of rare cancers.
Read the Statement
Latest News
-
17 Jul 2019
RCE-ESMO-ESO Training Course for Rare Cancer Patient Advocates 2019
From 29 November to 1 December 2019, Rare Cancers Europe will organise the next edition of the training course for rare cancer patient advocates.
-
21 Nov 2018
Rare Cancers Asia: Building Bridges to Improve Patient Care
ESMO launches new partnership to foster Asian-European collaboration on rare cancers
-
26 Oct 2018
RCE-ESMO-ESO Training Course for Rare Cancer Patient Advocates 2018
Patient advocate travel grants available